The Association between QuantiFERON-TB Gold Test and Clinical Manifestations of Uveitis in the United States
- PMID: 33945821
- PMCID: PMC8560650
- DOI: 10.1016/j.ajo.2021.04.024
The Association between QuantiFERON-TB Gold Test and Clinical Manifestations of Uveitis in the United States
Abstract
Purpose: To report the prevalence of QuantiFERON-TB Gold (QFT-G) positivity among uveitis patients compared to general population and to evaluate the differences in clinical features of uveitis.
Design: Retrospective cohort study.
Methods: SETTING: Institutional.
Patient population: 418 consecutive new uveitis patients, regardless of clinical suspicion, were tested for QFT-G.
Observation procedures: Demographics, TB risk factors, clinical characteristics of uveitis were collected.
Main outcome measures: The frequency of QFT-G positivity among uveitis patients and characteristic clinical features among QFT-G positive patients.
Results: QFT-G positivity was found in 60/418 patients with uveitis (14.4%, 95% CI: 11.18 - 18.14) higher than the general US population (5%, 95% CI: 4.2 - 5.8, p<.001). Age, gender and residence were similar between QFT-G positive and negative groups. Uveitis patients with positive QFT-G were more likely to be foreign born or have a recent travel history (OR:5.84; 95% CI: 2.83 - 12.05; p<.001). QFT-G positive patients were more likely to present with granulomatous uveitis (OR 2.90; 95%CI 1.36 - 6.21; p=.006). No significant association was found with specific clinical features such as choroiditis, retinal vasculitis, occlusive vasculitis, and serpiginoid choroiditis (p>.05 for each). Prevalence of TB-uveitis based on treatment response was 1.19%.
Conclusions: Our study demonstrates significantly higher prevalence of QFT-G positivity among uveitis patients compared to average US population. Characteristic signs of TB uveitis reported in endemic countries were not seen in this cohort. Implications of higher prevalence of QFT-G positivity among uveitis patients require further investigation.
Published by Elsevier Inc.
Similar articles
-
Looking for Ocular Tuberculosis: Prevalence and Clinical Manifestations of Patients with Uveitis and Positive QuantiFERON®-TB Gold Test.Ocul Immunol Inflamm. 2018;26(6):819-826. doi: 10.1080/09273948.2016.1245760. Epub 2016 Nov 16. Ocul Immunol Inflamm. 2018. PMID: 27849401
-
Utility of QuantiFERON®-TB Gold test in diagnosis and management of suspected tubercular uveitis in India.Int Ophthalmol. 2012 Jun;32(3):217-23. doi: 10.1007/s10792-012-9554-0. Epub 2012 Apr 15. Int Ophthalmol. 2012. PMID: 22527447
-
Clinical manifestations of patients with intraocular inflammation and positive QuantiFERON-TB gold in-tube test in a country nonendemic for tuberculosis.Am J Ophthalmol. 2014 Apr;157(4):754-61. doi: 10.1016/j.ajo.2013.11.013. Epub 2013 Nov 18. Am J Ophthalmol. 2014. PMID: 24262781
-
Role of interferon gamma release assay in the diagnosis and management of Mycobacterium tuberculosis-associated uveitis: a review.BMJ Open Ophthalmol. 2021 May 12;6(1):e000663. doi: 10.1136/bmjophth-2020-000663. eCollection 2021. BMJ Open Ophthalmol. 2021. PMID: 34046524 Free PMC article. Review.
-
Comparison of the QuantiFERON-TB Gold Plus and QuantiFERON-TB Gold In-Tube interferon-γ release assays: A systematic review and meta-analysis.Adv Med Sci. 2019 Sep;64(2):437-443. doi: 10.1016/j.advms.2019.09.001. Epub 2019 Oct 3. Adv Med Sci. 2019. PMID: 31586819
Cited by
-
Absence of Evidence as The Evidence Of Absence: The Curious Case of Latent Infection Causing Ocular Tuberculosis.Front Ophthalmol (Lausanne). 2022 May 2;2:874400. doi: 10.3389/fopht.2022.874400. Front Ophthalmol (Lausanne). 2022. PMID: 35911853 Free PMC article.
-
Antigen-Specific Intraocular Cytokine Responses Distinguish Ocular Tuberculosis From Undifferentiated Uveitis in Tuberculosis-Immunoreactive Patients.Am J Ophthalmol. 2023 Feb;246:31-41. doi: 10.1016/j.ajo.2022.08.029. Epub 2022 Sep 7. Am J Ophthalmol. 2023. PMID: 36087765 Free PMC article.
-
Antigen-specific polyfunctional cytotoxic T cells differentiate intraocular from peripheral blood immune responses in posterior uveitis.Clin Transl Immunology. 2025 May 15;14(5):e70036. doi: 10.1002/cti2.70036. eCollection 2025 May. Clin Transl Immunology. 2025. PMID: 40386650 Free PMC article.
-
Interferon gamma release assays for diagnosis of osteoarticular tuberculosis: A systematic review and meta-analysis.PLoS One. 2022 Jun 30;17(6):e0269234. doi: 10.1371/journal.pone.0269234. eCollection 2022. PLoS One. 2022. PMID: 35771875 Free PMC article.
References
-
- Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA. 1999;282(7):677–686. - PubMed
-
- Bloom BR, Atun R, Cohen T, et al. Tuberculosis. In: Holmes KK, Bertozzi S, Bloom BR, Jha P, eds. Major infectious diseases. 3rd edition. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2017. November 3 Chapter 11. - PubMed
-
- Bouza E, Merino P, Muñoz P, Sanchez-Carrillo C, Yáñez J, Cortés C. Ocular tuberculosis. A prospective study in a general hospital. Medicine (Baltimore). 1997;76(1):53–61. - PubMed
-
- Babu RB, Sudharshan S, Kumarasamy N, Therese L, Biswas J. Ocular tuberculosis in acquired immunodeficiency syndrome. Am J Ophthalmol. 2006;142(3):413–418. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources